U
39.30
0.33 (0.85%)
| 前收盘价格 | 38.97 |
| 收盘价格 | 39.20 |
| 成交量 | 1,044,500 |
| 平均成交量 (3个月) | 822,321 |
| 市值 | 3,566,310,400 |
| 价格/销量 (P/S) | 6.25 |
| 股市价格/股市净资产 (P/B) | 25.69 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2025 - 5 May 2025 |
| 营业毛利率 | -93.04% |
| 营业利益率 (TTM) | -102.62% |
| 稀释每股收益 (EPS TTM) | -5.83 |
| 季度收入增长率 (YOY) | 28.00% |
| 总债务/股东权益 (D/E MRQ) | 588.24% |
| 流动比率 (MRQ) | 2.40 |
| 营业现金流 (OCF TTM) | -389.94 M |
| 杠杆自由现金流 (LFCF TTM) | -172.94 M |
| 资产报酬率 (ROA TTM) | -24.51% |
| 股东权益报酬率 (ROE TTM) | -377.06% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Ultragenyx Pharmaceutical Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.7
| 分析师共识 | 4.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.70 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.20% |
| 机构持股比例 | 98.45% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 65.00 (Morgan Stanley, 65.39%) | 购买 |
| 65.00 (William Blair, 65.39%) | 购买 | |
| 中 | 65.00 (65.39%) | |
| 低 | 64.00 (Guggenheim, 62.85%) | 购买 |
| 平均值 | 64.67 (64.56%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 35.53 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 20 Jun 2025 | 64.00 (62.85%) | 购买 | 37.14 |
| William Blair | 28 May 2025 | 65.00 (65.39%) | 购买 | 34.35 |
| Morgan Stanley | 09 May 2025 | 65.00 (65.39%) | 购买 | 35.11 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合